Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

Market Cap	259.78B
Revenue (ttm)	34.99M
Net Income (ttm)	-488.25M
Shares Out	1.55B
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	70.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,341,300
Average Volume	14,173,828
Open	184.50
Previous Close	183.00
Day's Range	166.00 - 188.00
52-Week Range	51.00 - 277.00
Beta	0.72
RSI	58.96
Earnings Date	Nov 7, 2025

About TPE:6919

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Tai...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6919

Financial Performance

In 2024, TPE:6919's revenue was 44.43 million, an increase of 14.13% compared to the previous year's 38.93 million. Losses were -588.83 million, 20.5% more than in 2023.